WO2015168614A3 - Polymer compositions of histone deacetylase inhibitors and methods of use thereof - Google Patents

Polymer compositions of histone deacetylase inhibitors and methods of use thereof Download PDF

Info

Publication number
WO2015168614A3
WO2015168614A3 PCT/US2015/028877 US2015028877W WO2015168614A3 WO 2015168614 A3 WO2015168614 A3 WO 2015168614A3 US 2015028877 W US2015028877 W US 2015028877W WO 2015168614 A3 WO2015168614 A3 WO 2015168614A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
histone deacetylase
polymer compositions
deacetylase inhibitors
inhibitors
Prior art date
Application number
PCT/US2015/028877
Other languages
French (fr)
Other versions
WO2015168614A2 (en
Inventor
David OUPICKY
Mihaela C. STEFAN
Michael C. BIEWER
Original Assignee
Board Of Regents Of The University Of Nebraska
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents Of The University Of Nebraska, The Board Of Regents Of The University Of Texas System filed Critical Board Of Regents Of The University Of Nebraska
Publication of WO2015168614A2 publication Critical patent/WO2015168614A2/en
Publication of WO2015168614A3 publication Critical patent/WO2015168614A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nanoparticle compositions comprising amphiphilic block copolymer and methods for the delivery of a histone deacetylase inhibitor are provided.
PCT/US2015/028877 2014-05-01 2015-05-01 Polymer compositions of histone deacetylase inhibitors and methods of use thereof WO2015168614A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987189P 2014-05-01 2014-05-01
US61/987,189 2014-05-01

Publications (2)

Publication Number Publication Date
WO2015168614A2 WO2015168614A2 (en) 2015-11-05
WO2015168614A3 true WO2015168614A3 (en) 2015-12-30

Family

ID=54359506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/028877 WO2015168614A2 (en) 2014-05-01 2015-05-01 Polymer compositions of histone deacetylase inhibitors and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2015168614A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
KR20240016997A (en) * 2021-06-07 2024-02-06 고쿠리쯔 다이가쿠 호징 츠쿠바 다이가쿠 Polymerized valproic acid and its uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040837A2 (en) * 1998-02-06 1999-08-19 Biocrystal Ltd. Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
WO2012121862A2 (en) * 2011-02-17 2012-09-13 University Of Florida Research Foundation Valproic acid derivative compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040837A2 (en) * 1998-02-06 1999-08-19 Biocrystal Ltd. Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
WO2012121862A2 (en) * 2011-02-17 2012-09-13 University Of Florida Research Foundation Valproic acid derivative compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAMIDI ET AL.: "Vaproate--Loaded hydrogel nanoparticles: Preparation and characterization", JOURNAL OF APPLIED POLYMER SCIENCE, vol. 124, no. 6, 15 June 2012 (2012-06-15), pages 4686 - 4693, XP055245639 *
LEE ET AL.: "Polymeric micelle for tumor pH and folate-mediated targeting", JOURNAL OF CONTROLLED RELEASE., vol. 91, 28 August 2003 (2003-08-28), pages 103 - 113, XP004447896 *
ZHANG ET AL.: "Synthesis and in vitro drug release behavior of amphiphilic triblock copolymer nanoparticles based on poly (ethylene glycol) and polycaprolactone.", BIOMATERIALS, vol. 26, no. 33, November 2005 (2005-11-01), pages 6736 - 6742, XP027767642 *

Also Published As

Publication number Publication date
WO2015168614A2 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
HK1251571A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
HK1254756A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
HK1251549A1 (en) 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
HRP20181534T1 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
EP3471727A4 (en) Cxcr4 inhibitors and uses thereof
EP3472129A4 (en) Cxcr4 inhibitors and uses thereof
EP3362445A4 (en) Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3191533A4 (en) Polymers including one or more 1,1-disubstituted alkene compounds and polymer compositions thereof
EP3291809A4 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP3471726A4 (en) Cxcr4 inhibitors and uses thereof
EP3484478A4 (en) Histone deacetylase inhibitors for use in immunotherapy
EP3148572A4 (en) Compositions and methods of delivery of deubiquitinase inhibitors
EP3341007A4 (en) Malt1 inhibitors and uses thereof
EP3190100A4 (en) Polymerizable compound, polymer, polymerizable composition, and film
EP3148539A4 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP3218435A4 (en) Composition comprising polymer particles, a hydrocarbon-based oil and a hydrocarbon-based block copolymer, and process using the same
EP3129373A4 (en) Histone deacetylase inhibitors
EP3297992A4 (en) Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
EP3291810A4 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP3272742A4 (en) Histone deacetylase inhibitor, and preparation method and use thereof
WO2015168614A3 (en) Polymer compositions of histone deacetylase inhibitors and methods of use thereof
EP3849992A4 (en) Cd73 inhibitors and pharmaceutical uses thereof
EP3458444A4 (en) Histone deacetylase 6 inhibitors and use thereof
EP3474855A4 (en) Ck2 inhibitors, compositions and methods thereof
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15786069

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15786069

Country of ref document: EP

Kind code of ref document: A2